Status:
COMPLETED
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Leukemia
Myelodysplastic Syndromes
Eligibility:
All Genders
5-120 years
Brief Summary
RATIONALE: Studying samples of bone marrow from patients with cancer and from healthy volunteers in the laboratory may help doctors learn more about changes that occur in bone marrow stromal (connecti...
Detailed Description
OBJECTIVES: Primary * Determine abnormal stromal function in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or Fanconi anemia; in patients who were exposed to alkylatin...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Meets 1 of the following criteria:
- Diagnosis of acute myeloid leukemia or myelodysplastic syndromes and requires bone marrow aspiration/biopsy for clinical purposes
- Primary or secondary disease
- Diagnosis of Fanconi anemia by positive mitomycin C test (age 5 to 55 years)
- Received prior chemotherapy containing any of the following alkylating agents: mechlorethamine, chlorambucil, cyclophosphamide, melphalan, busulfan, or topoisomerase inhibitors
- Healthy volunteer (age 18 and over), meeting the following criteria:
- CBC normal
- WBC \> 1,000/mm³
- Hemoglobin \> 10 g/dL
- Platelet count \> 70,000/mm³
- No bone marrow metastases
- No evidence of non-hematopoietic malignancy
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- No clinical signs and symptoms of acute or subacute infection (viral, bacterial, or fungal infection)
- No allergy to lidocaine or xylocaine
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 6 months since prior cytotoxic or immunosuppressive agents
- No prior extensive pelvic radiotherapy (\> 20 Gy)
Exclusion
Key Trial Info
Start Date :
June 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00899795
Start Date
June 1 2002
End Date
October 1 2010
Last Update
December 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239-3098